Shares of Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $56.5714.
Several equities analysts recently commented on the company. Weiss Ratings lowered Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. Citigroup increased their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. TD Cowen lifted their price objective on shares of Royalty Pharma from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Bank of America restated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday.
View Our Latest Analysis on Royalty Pharma
Insider Activity
Institutional Investors Weigh In On Royalty Pharma
A number of hedge funds have recently bought and sold shares of the business. Morgan Stanley boosted its stake in shares of Royalty Pharma by 25.2% during the 4th quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock valued at $2,135,790,000 after buying an additional 11,110,115 shares during the last quarter. Capital International Investors grew its position in shares of Royalty Pharma by 14.3% during the fourth quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock worth $1,201,870,000 after buying an additional 3,891,615 shares in the last quarter. State Street Corp increased its stake in shares of Royalty Pharma by 3.7% in the fourth quarter. State Street Corp now owns 10,649,641 shares of the biopharmaceutical company’s stock worth $411,502,000 after buying an additional 376,888 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Royalty Pharma by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 7,719,843 shares of the biopharmaceutical company’s stock worth $297,465,000 after buying an additional 102,430 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Royalty Pharma by 9.7% in the fourth quarter. Victory Capital Management Inc. now owns 5,106,905 shares of the biopharmaceutical company’s stock valued at $197,331,000 after acquiring an additional 449,498 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.
Key Royalty Pharma News
Here are the key news stories impacting Royalty Pharma this week:
- Positive Sentiment: Royalty receipts and guidance increased. Portfolio Receipts rose 6% to $773 million, while Royalty Receipts grew 14%. Management raised its 2026 Portfolio Receipts outlook to $3.4 billion-$3.5 billion, signaling confidence in the underlying royalty portfolio. Royalty Pharma reports second quarter 2026 results
- Positive Sentiment: Cash generation remained strong. Net cash provided by operating activities reached $728 million, supporting Royalty Pharma’s ability to fund acquisitions, dividends and other shareholder returns. Adjusted earnings of $1.32 per share also exceeded the $1.27 consensus estimate and increased from $1.14 a year earlier. Royalty Pharma Q2 earnings report
- Neutral Sentiment: Reported results contain a measure-related discrepancy. MarketBeat cited GAAP EPS of $0.04 and revenue of $674.1 million, below consensus revenue of $758.9 million, while Zacks highlighted adjusted EPS of $1.32 and described revenue as beating estimates. Investors are likely emphasizing royalty receipts and adjusted earnings, but the difference between GAAP and adjusted results may add volatility. Royalty Pharma earnings report
- Negative Sentiment: Valuation and target-price risks remain. Royalty Pharma trades near the upper end of its 52-week range, while one brokerage consensus target of $56.57 is below the recent trading level. That could limit near-term upside unless the raised guidance translates into further analyst upgrades. Royalty Pharma target price coverage
Royalty Pharma Trading Up 0.5%
NASDAQ:RPRX opened at $57.75 on Thursday. The business’s 50-day moving average is $56.39 and its two-hundred day moving average is $50.30. The firm has a market capitalization of $33.25 billion, a PE ratio of 39.29, a price-to-earnings-growth ratio of 10.18 and a beta of 0.43. Royalty Pharma has a 12 month low of $34.08 and a 12 month high of $60.44. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66.
Royalty Pharma (NASDAQ:RPRX – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.05. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The company had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Research analysts predict that Royalty Pharma will post 5.18 earnings per share for the current fiscal year.
Royalty Pharma Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.235 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma’s payout ratio is currently 63.95%.
Royalty Pharma Company Profile
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.
Featured Stories
- Five stocks we like better than Royalty Pharma
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
